Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Liabilities and Shareholders Equity (2019 - 2026)

Pliant Therapeutics has reported Liabilities and Shareholders Equity over the past 8 years, most recently at $202.6 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 41.24% to $202.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Mar 2026, down 39.91% year-over-year, with the annual reading at $225.2 million for FY2025, 43.26% down from the prior year.
  • Liabilities and Shareholders Equity was $202.6 million for Q1 2026 at Pliant Therapeutics, down from $225.2 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $597.9 million in Q1 2023 and troughed at $184.6 million in Q2 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $377.2 million (2022), against an average of $384.2 million.
  • Year-over-year, Liabilities and Shareholders Equity skyrocketed 211.39% in 2023 and then plummeted 43.26% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $350.6 million in 2022, then surged by 46.07% to $512.2 million in 2023, then fell by 22.49% to $396.9 million in 2024, then tumbled by 43.26% to $225.2 million in 2025, then decreased by 10.05% to $202.6 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Liabilities and Shareholders Equity are $202.6 million (Q1 2026), $225.2 million (Q4 2025), and $276.6 million (Q3 2025).